{"id":"chlorthalidone","rwe":[],"_fda":{"id":"a126115d-3e90-411b-91de-ccde9090e90f","set_id":"01065eda-7515-46bc-b858-a062c3aa35bd","openfda":{"nui":["N0000175359","N0000175420"],"upc":["0329300333015","0329300334012"],"unii":["Q0MQD1073Q"],"route":["ORAL"],"rxcui":["197499","197500"],"spl_id":["a126115d-3e90-411b-91de-ccde9090e90f"],"brand_name":["Chlorthalidone"],"spl_set_id":["01065eda-7515-46bc-b858-a062c3aa35bd"],"package_ndc":["29300-333-10","29300-333-01","29300-334-01","29300-334-10"],"product_ndc":["29300-333","29300-334"],"generic_name":["CHLORTHALIDONE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Increased Diuresis [PE]"],"substance_name":["CHLORTHALIDONE"],"pharm_class_epc":["Thiazide-like Diuretic [EPC]"],"manufacturer_name":["Unichem Pharmaceuticals (USA), Inc."],"application_number":["ANDA211627"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Chlorthalidone should be used with caution in severe renal disease. In patients with renal disease, chlorthalidone or related drugs may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Chlorthalidone should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics, which are structurally related to chlorthalidone. However, systemic lupus erythematosus has not been reported following chlorthalidone administration."],"pregnancy":["Pregnancy Teratogenic Effects. Pregnancy Category B Reproduction studies have been performed in the rat and the rabbit at doses up to 420 times the human dose and have revealed no evidence of harm to the fetus due to chlorthalidone. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nonteratogenic Effects Thiazides cross the placental barrier and appear in cord blood. The use of chlorthalidone and related drugs in pregnant women requires that the anticipated benefits of the drug be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in the adult. Nursing Mothers Thiazides are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from chlorthalidone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in children have not been established."],"overdosage":["OVERDOSAGE Symptoms of acute overdosage include nausea, weakness, dizziness, and disturbances of electrolyte balance. The oral LD 50 of the drug in the mouse and the rat is more than 25,000 mg/kg body weight. The minimum lethal dose (MLD) in humans has not been established. There is no specific antidote, but gastric lavage is recommended, followed by supportive treatment. Where necessary, this may include intravenous dextrose-saline with potassium, administered with caution."],"description":["DESCRIPTION Chlorthalidone, USP an oral antihypertensive/diuretic. It is a monosulfamyl diuretic that differs chemically from thiazide diuretics in that a double-ring system is incorporated in its structure. It is 2-chloro-5(1-hydroxy-3-oxo-1- isoindolinyl) benzenesulfonamide with the following structural formula: Molecular Formula: C 14 H 11 ClN 2 O 4 S Molecular weight: 338.77 Chlorthalidone, USP is practically insoluble in water, in ether, and in chloroform; soluble in methanol; slightly soluble in ethanol. Chlorthalidone tablets, USP are available containing either 25 mg or 50 mg of chlorthalidone, USP and the following inactive ingredients: colloidal silicon dioxide, D&C Yellow No. 10 Aluminum Lake, microcrystalline cellulose, pregelatinized starch (maize), sodium starch glycolate (potato), stearic acid. The 50 mg tablets also contain FD&C Blue No.1 Aluminum Lake. Image"],"precautions":["PRECAUTIONS General Hypokalemia may develop with chlorthalidone as with any other diuretic, especially with brisk diuresis when severe cirrhosis is present or during concomitant use of corticosteroids or ACTH. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia especially with reference to myocardial activity. Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients in hot weather, appropriate therapy is water restriction, rather than administration of salt except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice. Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving chlorthalidone. Thiazide-like diuretics have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient. If progressive renal impairment becomes evident, as indicated by a rising nonprotein nitrogen or blood urea nitrogen, a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy. Calcium excretion is decreased by thiazide-like drugs. Pathological changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been observed in few patients on thiazide therapy. The common complications of hyperparathyroidism such as renal lithiasis, bone resorption and peptic ulceration have not been seen. Information for Patients Patients should inform their physician if they have: (1) had an allergic reaction to chlorthalidone or other diuretics or have asthma, (2) kidney disease, (3) liver disease, (4) gout, (5) systemic lupus erythematosus, or (6) been taking other drugs such as cortisone, digitalis, lithium carbonate, or drugs for diabetes. Patients should be cautioned to contact their physician if they experience any of the following symptoms of potassium loss: excess thirst, tiredness, drowsiness, restlessness, muscle pains or cramps, nausea, vomiting, or increased heart rate or pulse. Patients should also be cautioned that taking alcohol can increase the chance of dizziness occurring. Laboratory Tests Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. All patients receiving chlorthalidone should be observed for clinical signs of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Drug Interactions Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic peripheral adrenergic blocking drugs. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Higher dosage of oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during chlorthalidone administration. Chlorthalidone and related drugs may increase the responsiveness to tubocurarine. Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Drug/Laboratory Test Interactions Chlorthalidone and related drugs may decrease serum PBI levels without signs of thyroid disturbance. Carcinogenesis , Mutagenesis , Impairment of Fertility No information is available. Pregnancy Teratogenic Effects. Pregnancy Category B Reproduction studies have been performed in the rat and the rabbit at doses up to 420 times the human dose and have revealed no evidence of harm to the fetus due to chlorthalidone. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nonteratogenic Effects Thiazides cross the placental barrier and appear in cord blood. The use of chlorthalidone and related drugs in pregnant women requires that the anticipated benefits of the drug be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in the adult. Nursing Mothers Thiazides are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from chlorthalidone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in children have not been established. ADVERSE REACTIONS The following adverse reactions have been observed, but there is not enough systematic collection of data to support an estimate of their frequency. Gastrointestinal System Reactions: anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis. Central Nervous System Reactions: dizziness, vertigo, paresthesias, headache, xanthopsia. Hematologic Reactions: leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia. Dermatologic-Hypersensitivity Reactions: purpura, photosensitivity, rash, urticaria, necrotizing angiitis (vasculitis, cutaneous vasculitis), Lyell's syndrome (toxic epidermal necrolysis). Cardiovascular Reactions: orthostatic hypotension may occur and may be aggravated by alcohol, barbiturates, or narcotics. Other Adverse Reactions: hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness, impotence. Whenever adverse reactions are moderate or severe, chlorthalidone dosage should be reduced or therapy withdrawn. OVERDOSAGE Symptoms of acute overdosage include nausea, weakness, dizziness, and disturbances of electrolyte balance. The oral LD 50 of the drug in the mouse and the rat is more than 25,000 mg/kg body weight. The minimum lethal dose (MLD) in humans has not been established. There is no specific antidote, but gastric lavage is recommended, followed by supportive treatment. Where necessary, this may include intravenous dextrose-saline with potassium, administered with caution."],"how_supplied":["HOW SUPPLIED Chlorthalidone Tablets, USP are available containing 25 mg or 50 mg of chlorthalidone, USP. The 25 mg tablets are light yellow, round, flat faced, beveled edged uncoated tablets, debossed with \"U\" on one side and \"3\" on other side. They are available as follows: NDC 29300-333-01 Bottles of 100 tablets NDC 29300-333-10 Bottles of 1,000 tablets The 50 mg tablets are light green, round, scored, flat faced, beveled edged uncoated tablet debossed with 'U' on upper side of the score and '4' on lower side of the score on one side of the tablet and plain on the other side. They are available as follows: NDC 29300-334-01 Bottles of 100 tablets NDC 29300-334-10 Bottles of 1,000 tablets Store at 20° to 25°C (68° to 77°F). [see USP for Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure."],"pediatric_use":["Pediatric Use Safety and effectiveness in children have not been established."],"effective_time":"20221124","nursing_mothers":["Nursing Mothers Thiazides are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from chlorthalidone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"laboratory_tests":["Laboratory Tests Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. All patients receiving chlorthalidone should be observed for clinical signs of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions have been observed, but there is not enough systematic collection of data to support an estimate of their frequency. Gastrointestinal System Reactions: anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis. Central Nervous System Reactions: dizziness, vertigo, paresthesias, headache, xanthopsia. Hematologic Reactions: leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia. Dermatologic-Hypersensitivity Reactions: purpura, photosensitivity, rash, urticaria, necrotizing angiitis (vasculitis, cutaneous vasculitis), Lyell's syndrome (toxic epidermal necrolysis). Cardiovascular Reactions: orthostatic hypotension may occur and may be aggravated by alcohol, barbiturates, or narcotics. Other Adverse Reactions: hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness, impotence. Whenever adverse reactions are moderate or severe, chlorthalidone dosage should be reduced or therapy withdrawn."],"contraindications":["CONTRAINDICATIONS Anuria. Known hypersensitivity to chlorthalidone or other sulfonamide-derived drugs."],"drug_interactions":["Drug Interactions Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic peripheral adrenergic blocking drugs. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Higher dosage of oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during chlorthalidone administration. Chlorthalidone and related drugs may increase the responsiveness to tubocurarine. Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Chlorthalidone is an oral diuretic with prolonged action (48-72 hours) and low toxicity. The major portion of the drug is excreted unchanged by the kidneys. The diuretic effect of the drug occurs in approximately 2.6 hours and continues for up to 72 hours. The mean half-life following a 50 to 200 mg dose is 40 hours. In the first order of absorption, the elimination half-life is 53 hours following a 50 mg dose, and 60 hours following a 100 mg dose. Approximately 75 percent of the drug is bound to plasma proteins, 58 percent of the drug being bound to albumin. This is caused by an increased affinity of the drug to erythrocyte carbonic anhydrase. Non renal routes of elimination have yet to be clarified. Data are not available regarding percentage of dose as unchanged drug and metabolites, concentration of the drug in body fluids, degree of uptake by a particular organ or in the fetus, or passage across the blood-brain barrier. The drug produces copious diuresis with greatly increased excretion of sodium and chloride. At maximal therapeutic dosage, chlorthalidone is approximately equal in its diuretic effect to comparable maximal therapeutic doses of benzothiadiazine diuretics. The site of action appears to be the cortical diluting segment of the ascending limb of Henle's loop of the nephron."],"indications_and_usage":["INDICATIONS AND USAGE Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS, below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate."],"nonteratogenic_effects":["Nonteratogenic Effects Thiazides cross the placental barrier and appear in cord blood. The use of chlorthalidone and related drugs in pregnant women requires that the anticipated benefits of the drug be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in the adult."],"information_for_patients":["Information for Patients Patients should inform their physician if they have: (1) had an allergic reaction to chlorthalidone or other diuretics or have asthma, (2) kidney disease, (3) liver disease, (4) gout, (5) systemic lupus erythematosus, or (6) been taking other drugs such as cortisone, digitalis, lithium carbonate, or drugs for diabetes. Patients should be cautioned to contact their physician if they experience any of the following symptoms of potassium loss: excess thirst, tiredness, drowsiness, restlessness, muscle pains or cramps, nausea, vomiting, or increased heart rate or pulse. Patients should also be cautioned that taking alcohol can increase the chance of dizziness occurring."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Therapy should be initiated with the lowest possible dose. This dose should be titrated according to individual patient response to gain maximal therapeutic benefit while maintaining lowest dosage possible. A single dose given in the morning with food is recommended; divided daily doses are unnecessary. Hypertension Initiation: Therapy, in most patients, should be initiated with a single daily dose of 25 mg. If the response is insufficient after a suitable trial, the dosage may be increased to a single daily dose of 50 mg. If additional control is required, the dosage of chlorthalidone may be increased to 100 mg once daily or a second antihypertensive drug (step 2 therapy) may be added. Dosage above 100 mg daily usually does not increase effectiveness. Increases in serum uric acid and decreases in serum potassium are dose-related over the 25 to 100 mg/day range. Maintenance: Maintenance doses may be lower than initial doses and should be adjusted according to individual patient response. Effectiveness is well sustained during continued use. Edema Initiation: Adults, initially 50 to 100 mg daily, or 100 mg on alternate days. Some patients may require 150 to 200 mg at these intervals or up to 200 mg daily. Dosages above this level, however, do not usually produce a greater response. Maintenance: Maintenance doses may often be lower than initial doses and should be adjusted according to individual patient response. Effectiveness is well sustained during continued use."],"spl_product_data_elements":["Chlorthalidone Chlorthalidone CHLORTHALIDONE CHLORTHALIDONE D&C YELLOW NO. 10 MICROCRYSTALLINE CELLULOSE SILICON DIOXIDE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN STEARIC ACID Light Yellow U;3 Chlorthalidone Chlorthalidone CHLORTHALIDONE CHLORTHALIDONE D&C YELLOW NO. 10 FD&C BLUE NO. 1 MICROCRYSTALLINE CELLULOSE SILICON DIOXIDE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN STEARIC ACID Light Green U;4"],"animal_pharmacology_and_or_toxicology":["ANIMAL PHARMACOLOGY AND OR TOXICOLOGY Biochemical studies in animals have suggested reasons for the prolonged effect of chlorthalidone. Absorption from the gastrointestinal tract is slow due to its low solubility. After passage to the liver, some of the drug enters the general circulation, while some is excreted in the bile, to be reabsorbed later. In the general circulation, it is distributed widely to the tissues, but is taken up in highest concentrations by the kidneys, where amounts have been found 72 hours after ingestion, long after it has disappeared from other tissues. The drug is excreted unchanged in the urine. Please address medical inquiries to Unichem's toll free # 1-866-562-4616. Manufactured by: UNICHEM LABORATORIES LTD. Ind. Area, Meerut Road, Ghaziabad – 201 003, India Manufactured for: East Brunswick, NJ 08816 02-R-03/2019 13010246 Image"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Container Label - 25 mg - 100 T Container Label - 50 mg - 100 T"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1220 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1144 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1011 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"871 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"790 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"731 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"674 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"668 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"633 reports"},{"date":"","signal":"HYPERTENSION","source":"FDA FAERS","actionTaken":"531 reports"}],"drugInteractions":[{"drug":"Other antihypertensive drugs","action":"Monitor","effect":"Potentiates the action of other antihypertensive drugs."},{"drug":"Digitalis","action":"Monitor","effect":"May influence serum electrolytes."},{"drug":"Insulin","action":"Monitor","effect":"May increase insulin requirements."},{"drug":"Oral hypoglycemics","action":"Monitor","effect":"May require higher dosage of oral hypoglycemics."},{"drug":"Tubocurarine","action":"Monitor","effect":"May increase responsiveness to tubocurarine."},{"drug":"Norepinephrine","action":"Monitor","effect":"May decrease arterial responsiveness to norepinephrine."}],"commonSideEffects":[{"effect":"Anorexia","drugRate":"","severity":"mild"},{"effect":"Gastric irritation","drugRate":"","severity":"mild"},{"effect":"Nausea","drugRate":"","severity":"mild"},{"effect":"Vomiting","drugRate":"","severity":"moderate"},{"effect":"Cramping","drugRate":"","severity":"mild"},{"effect":"Diarrhea","drugRate":"","severity":"mild"},{"effect":"Constipation","drugRate":"","severity":"mild"},{"effect":"Jaundice","drugRate":"","severity":"serious"},{"effect":"Pancreatitis","drugRate":"","severity":"serious"},{"effect":"Dizziness","drugRate":"","severity":"mild"},{"effect":"Vertigo","drugRate":"","severity":"mild"},{"effect":"Paresthesias","drugRate":"","severity":"mild"},{"effect":"Headache","drugRate":"","severity":"mild"},{"effect":"Xanthopsia","drugRate":"","severity":"mild"},{"effect":"Leukopenia","drugRate":"","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"","severity":"serious"},{"effect":"Thrombocytopenia","drugRate":"","severity":"serious"},{"effect":"Aplastic anemia","drugRate":"","severity":"serious"},{"effect":"Purpura","drugRate":"","severity":"serious"},{"effect":"Photosensitivity","drugRate":"","severity":"mild"},{"effect":"Rash","drugRate":"","severity":"mild"},{"effect":"Urticaria","drugRate":"","severity":"mild"},{"effect":"Necrotizing angiitis","drugRate":"","severity":"serious"},{"effect":"Lyell's syndrome","drugRate":"","severity":"serious"},{"effect":"Orthostatic hypotension","drugRate":"","severity":"moderate"},{"effect":"Hyperglycemia","drugRate":"","severity":"moderate"},{"effect":"Glycosuria","drugRate":"","severity":"mild"},{"effect":"Hyperuricemia","drugRate":"","severity":"moderate"},{"effect":"Muscle spasm","drugRate":"","severity":"mild"},{"effect":"Weakness","drugRate":"","severity":"mild"},{"effect":"Restlessness","drugRate":"","severity":"mild"},{"effect":"Impotence","drugRate":"","severity":"moderate"}],"contraindications":["Anuria","Known hypersensitivity to chlorthalidone or other sulfonamide-derived drugs"],"specialPopulations":{"Pregnancy":"Routine use in healthy pregnant women is inappropriate. Use is indicated in pregnancy when edema is due to pathologic causes.","Geriatric use":"Use with caution in elderly patients. Monitor for electrolyte imbalances and orthostatic hypotension.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"Use with caution in patients with renal impairment. Monitor electrolytes and renal function.","Hepatic impairment":"Use with caution in patients with hepatic impairment. Monitor for signs of hepatic encephalopathy."},"seriousAdverseEvents":[{"event":"Jaundice","detail":"","severity":"serious","incidence":""},{"event":"Pancreatitis","detail":"","severity":"serious","incidence":""},{"event":"Leukopenia","detail":"","severity":"serious","incidence":""},{"event":"Agranulocytosis","detail":"","severity":"serious","incidence":""},{"event":"Thrombocytopenia","detail":"","severity":"serious","incidence":""},{"event":"Aplastic anemia","detail":"","severity":"serious","incidence":""},{"event":"Necrotizing angiitis","detail":"","severity":"serious","incidence":""},{"event":"Lyell's syndrome","detail":"","severity":"serious","incidence":""},{"event":"Orthostatic hypotension","detail":"","severity":"serious","incidence":""}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1055","moleculeType":"Small molecule","molecularWeight":"338.77"},"aliases":["chlortalidone"],"patents":[{"type":"","filed":"","status":"","expires":"","territory":"","description":"","patentNumber":""}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0982/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$36","description":"CHLORTHALIDONE 25 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHLORTHALIDONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:23:10.218532+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:23:10.218434+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:23:15.658994+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:23:09.336698+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORTHALIDONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:23:16.258714+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:07.514620+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:07.514652+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:07.514658+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:23:17.796659+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thiazide-sensitive sodium-chloride cotransporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:23:17.364789+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1055/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:23:16.999528+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA211627","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:07.514661+00:00"}},"allNames":"CHLORTHALIDONE, chlortalidone, chlorthalidone","offLabel":[],"timeline":[{"date":"","type":"positive","milestone":"FDA approval for hypertension","regulator":"FDA","description":"Chlorthalidone received FDA approval for the management of hypertension."},{"date":"","type":"positive","milestone":"FDA approval for edema","regulator":"FDA","description":"Chlorthalidone received FDA approval for the management of edema associated with various conditions."},{"date":"","type":"neutral","milestone":"Phase 1 initiation","regulator":"none","description":"Initial clinical trials began to evaluate the safety and pharmacokinetics of chlorthalidone."},{"date":"","type":"neutral","milestone":"Phase 2 initiation","regulator":"none","description":"Phase 2 trials began to evaluate the efficacy and safety of chlorthalidone in various indications."},{"date":"","type":"neutral","milestone":"Phase 3 initiation","regulator":"none","description":"Phase 3 trials began to confirm the efficacy and safety of chlorthalidone in larger patient populations."},{"date":"","type":"positive","milestone":"Label expansion for edema in pregnancy","regulator":"FDA","description":"Chlorthalidone received a label expansion for the management of edema in pregnancy due to pathologic causes."},{"date":"","type":"negative","milestone":"Generic competition begins","regulator":"none","description":"Generic versions of chlorthalidone entered the market, increasing competition and reducing prices."},{"date":"","type":"neutral","milestone":"Phase 4 study initiation","regulator":"none","description":"Post-marketing studies began to further evaluate the long-term safety and efficacy of chlorthalidone."}],"_dailymed":{"setId":"da50019b-60ea-47b3-a355-4ab48efcbe3d","title":"CHLORTHALIDONE TABLET [BRYANT RANCH PREPACK]"},"ecosystem":[],"mechanism":{"target":"Na+/Cl− cotransporter","novelty":"me-too","modality":"small molecule","drugClass":"Thiazide-like Diuretic [EPC]","explanation":"","oneSentence":"","technicalDetail":"Chlorthalidone binds to the Na+/Cl− cotransporter in the distal convoluted tubule, inhibiting sodium reabsorption and increasing urinary excretion. It has a longer half-life compared to other thiazides, which contributes to its sustained efficacy."},"_scrapedAt":"2026-03-27T23:43:23.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"notes":"","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"yes"},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:23:20.316262+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"name":"Hydrochlorothiazide","slug":"hydrochlorothiazide","company":"Various","advantage":"Widely used, well-established in clinical practice."},{"name":"Indapamide","slug":"indapamide","company":"Various","advantage":"Effective in reducing blood pressure and edema, similar mechanism of action."},{"name":"Torsemide","slug":"torsemide","company":"Various","advantage":"Loop diuretic with a longer duration of action."},{"name":"Furosemide","slug":"furosemide","company":"Various","advantage":"Loop diuretic with rapid onset of action."},{"name":"Spironolactone","slug":"spironolactone","company":"Various","advantage":"Aldosterone antagonist, useful in heart failure and hypertension."}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"line":"1L","name":"Hypertension","notes":"","regulator":"FDA","approvalDate":""},{"line":"adjuvant","name":"Edema associated with congestive heart failure","notes":"","regulator":"FDA","approvalDate":""},{"line":"adjuvant","name":"Edema associated with hepatic cirrhosis","notes":"","regulator":"FDA","approvalDate":""},{"line":"adjuvant","name":"Edema due to corticosteroid and estrogen therapy","notes":"","regulator":"FDA","approvalDate":""},{"line":"adjuvant","name":"Edema due to renal dysfunction","notes":"","regulator":"FDA","approvalDate":""}],"offLabel":[{"name":"Edema due to pathologic causes in pregnancy","notes":"Use is guided by clinical judgment and patient-specific factors.","evidenceLevel":"moderate"}],"pipeline":[{"name":"Cardiac effects of mineralocorticoid receptor antagonism after preeclampsia","notes":"","phase":"Phase 2","status":"recruiting"},{"name":"Indapamide and chlorthalidone to reduce urine supersaturation for kidney stone prevention","notes":"","phase":"Phase 2","status":"recruiting"},{"name":"Spironolactone in CKD enabled by chlorthalidone","notes":"","phase":"Phase 2","status":"unknown"},{"name":"Safety and efficacy of chlorthalidone in type 1 diabetes","notes":"","phase":"Phase 2","status":"terminated"},{"name":"Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension","notes":"","phase":"Phase 3","status":"withdrawn"}]},"labelChanges":[],"relatedDrugs":[{"name":"Indapamide","slug":"indapamide","company":"Rising Pharma Holdings, Inc.","genericName":"INDAPAMIDE","relationship":"same-class"},{"name":"Metolazone","slug":"metolazone","company":"Bryant Ranch Prepack","genericName":"METOLAZONE","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05293756","phase":"NA","title":"OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)","status":"RECRUITING","sponsor":"Case Western Reserve University","startDate":"2021-02-14","conditions":"Hypertension, Self-Management, Technology","enrollment":208},{"nctId":"NCT06287580","phase":"EARLY_PHASE1","title":"Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-08-15","conditions":"Essential Hypertension, Older Adults","enrollment":27},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT05370599","phase":"PHASE2","title":"Hypertension in Young Adults Trial","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2022-04-15","conditions":"Hypertension","enrollment":36},{"nctId":"NCT05593055","phase":"PHASE4","title":"Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-08-25","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":75},{"nctId":"NCT05171686","phase":"PHASE4","title":"Diuretics and Volume Overload in Early CKD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2023-02-01","conditions":"Chronic Kidney Disease, Hypertension","enrollment":49},{"nctId":"NCT02483936","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Arterial Hypertension","enrollment":""},{"nctId":"NCT02493322","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT07238400","phase":"PHASE2","title":"Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-12-01","conditions":"Hypertension","enrollment":90},{"nctId":"NCT07225764","phase":"PHASE4","title":"CaOx Stone Prevention","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-10-23","conditions":"Kidney Stones","enrollment":80},{"nctId":"NCT04519164","phase":"PHASE4","title":"Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-01","conditions":"Metabolic Syndrome, Hypertension, Overweight and Obesity","enrollment":79},{"nctId":"NCT02847338","phase":"PHASE4","title":"Comparison of Optimal Hypertension Regimens","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2016-11","conditions":"Hypertension","enrollment":940},{"nctId":"NCT07116863","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Kyungdong Pharmaceutical Co., Ltd.","startDate":"2022-06-21","conditions":"Essential Hypertension","enrollment":286},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":"Acute Heart Failure, Diuretics Drug Reactions","enrollment":107},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT01191450","phase":"PHASE3","title":"Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":"Arterial Hypertension","enrollment":246},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT05915286","phase":"PHASE4","title":"Diuretic Use in Hemodialysis Patients With Residual Renal Function","status":"SUSPENDED","sponsor":"University of Alberta","startDate":"2023-05-29","conditions":"End Stage Renal Disease on Dialysis","enrollment":34},{"nctId":"NCT04927299","phase":"PHASE3","title":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-06-30","conditions":"Essential Arterial Hypertension","enrollment":163},{"nctId":"NCT06111885","phase":"PHASE2","title":"Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-01","conditions":"Kidney Stone","enrollment":99},{"nctId":"NCT06282549","phase":"","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2022-06-08","conditions":"Essential Hypertension","enrollment":1219},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT03662620","phase":"PHASE1","title":"Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-05","conditions":"Hypertension","enrollment":67},{"nctId":"NCT02185417","phase":"PHASE3","title":"Diuretic Comparison Project","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-06-15","conditions":"Hypertension","enrollment":20723},{"nctId":"NCT00006294","phase":"","title":"Genetics of Hypertension Associated Treatments (GenHAT)","status":"COMPLETED","sponsor":"Donna Arnett, 257-5678","startDate":"1999-09","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":37939},{"nctId":"NCT04470830","phase":"","title":"A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2019-09-11","conditions":"Essential Hypertension","enrollment":718},{"nctId":"NCT02665117","phase":"NA","title":"Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-01","conditions":"Hypertension","enrollment":61},{"nctId":"NCT05275907","phase":"PHASE4","title":"Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2022-07-12","conditions":"High Blood Pressure, Liver Transplant, Renal Function Abnormal","enrollment":""},{"nctId":"NCT05199129","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-11-17","conditions":"Hypertension","enrollment":166},{"nctId":"NCT04830449","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-10-29","conditions":"Hypertension","enrollment":122},{"nctId":"NCT04820907","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-10-27","conditions":"Hypertension","enrollment":123},{"nctId":"NCT05222191","phase":"PHASE2","title":"Spironolactone in CKD Enabled by Chlorthalidone: PILOT","status":"UNKNOWN","sponsor":"Indiana Institute for Medical Research","startDate":"2022-02-01","conditions":"Renal Insufficiency, Chronic Hypertension","enrollment":24},{"nctId":"NCT05976438","phase":"NA","title":"Skin Sodium and Salt Sensitivity of Blood Pressure","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2023-08","conditions":"Hypertension","enrollment":60},{"nctId":"NCT02841280","phase":"PHASE2","title":"Chlorthalidone in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-07","conditions":"Renal Insufficiency, Chronic, Hypertension","enrollment":160},{"nctId":"NCT02711670","phase":"NA","title":"Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium","status":"COMPLETED","sponsor":"VA New York Harbor Healthcare System","startDate":"2014-02","conditions":"Kidney Stones","enrollment":10},{"nctId":"NCT05580510","phase":"PHASE2, PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":"Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":160},{"nctId":"NCT03666351","phase":"PHASE4","title":"Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-18","conditions":"Aortic Stenosis, Aortic Regurgitation, Hypertension","enrollment":128},{"nctId":"NCT05462535","phase":"","title":"An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-02-26","conditions":"Hypertension,Essential","enrollment":4785},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT04192110","phase":"PHASE4","title":"Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2020-08-11","conditions":"Chronic Kidney Disease","enrollment":""},{"nctId":"NCT05090449","phase":"PHASE1","title":"Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2019-05-01","conditions":"Healthy","enrollment":36},{"nctId":"NCT05077475","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers","status":"UNKNOWN","sponsor":"AJU Pharm Co., Ltd.","startDate":"2021-09-24","conditions":"Hypertension","enrollment":60},{"nctId":"NCT05077462","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers","status":"UNKNOWN","sponsor":"AJU Pharm Co., Ltd.","startDate":"2021-09-17","conditions":"Hypertension","enrollment":60},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04757532","phase":"PHASE1","title":"Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-12-03","conditions":"Healthy Volunteers","enrollment":9},{"nctId":"NCT03325114","phase":"PHASE2","title":"Safety and Efficacy of Chlorthalidone in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2019-06-28","conditions":"Type 1 Diabetes Mellitus, Hypercalciuria","enrollment":1},{"nctId":"NCT03923933","phase":"PHASE2","title":"Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial","status":"COMPLETED","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2019-06-18","conditions":"Renal Insufficiency, Chronic","enrollment":34},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":"Arterial Hypertension","enrollment":94},{"nctId":"NCT04393493","phase":"PHASE2","title":"The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2017-07-01","conditions":"Cardiorenal Syndrome","enrollment":80},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT02357004","phase":"NA","title":"Mechanisms of Refractory Hypertension (Carvedilol)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2015-02","conditions":"Hypertensive","enrollment":""},{"nctId":"NCT03928145","phase":"PHASE3","title":"Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-11-13","conditions":"Hypertension","enrollment":84},{"nctId":"NCT02236520","phase":"PHASE2","title":"Tissue Sodium in Pre-hypertensive Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-09","conditions":"Hypertension","enrollment":71},{"nctId":"NCT01973335","phase":"PHASE4","title":"Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2013-11","conditions":"Heart Failure","enrollment":34},{"nctId":"NCT03156634","phase":"NA","title":"A Pilot Study of the Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-04-15","conditions":"Patient Education","enrollment":118},{"nctId":"NCT00353652","phase":"PHASE4","title":"Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-01","conditions":"Hypertension","enrollment":166},{"nctId":"NCT01083017","phase":"","title":"Resistant Arterial Hypertension Cohort Study","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2011-04","conditions":"Hypertension, Essential Hypertension, Resistant Hypertension","enrollment":74},{"nctId":"NCT02814552","phase":"NA","title":"OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06-18","conditions":"High Blood Pressure","enrollment":47},{"nctId":"NCT03560804","phase":"NA","title":"Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2014-11-10","conditions":"Arterial Stiffness, Ambulatory Blood Pressure Monitoring","enrollment":60},{"nctId":"NCT02896621","phase":"PHASE3","title":"Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12-07","conditions":"Hypertension, Sleep Apnea","enrollment":69},{"nctId":"NCT01203852","phase":"PHASE4","title":"Pharmacogenomic Evaluation of Antihypertensive Responses 2","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-08","conditions":"Hypertension","enrollment":839},{"nctId":"NCT02502981","phase":"PHASE4","title":"Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD","status":"UNKNOWN","sponsor":"University Hospital Birmingham","startDate":"2014-06","conditions":"Renal Insufficiency, Chronic, Cardio-Renal Syndrome","enrollment":154},{"nctId":"NCT02591628","phase":"NA","title":"Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2015-08","conditions":"Hypertension","enrollment":2027},{"nctId":"NCT01748123","phase":"PHASE4","title":"EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2016-08","conditions":"Hypertension","enrollment":""},{"nctId":"NCT03226340","phase":"PHASE4","title":"S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-12-02","conditions":"Essential Hypertension","enrollment":170},{"nctId":"NCT02644395","phase":"PHASE3","title":"Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-01-18","conditions":"Hypertension, Kidney Transplantation","enrollment":49},{"nctId":"NCT02030314","phase":"PHASE4","title":"The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2013-07","conditions":"Resistant Hypertension in Kidney Transplant Patients","enrollment":""},{"nctId":"NCT02121041","phase":"NA","title":"Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study","status":"COMPLETED","sponsor":"Anthony J Viera, MD, MPH","startDate":"2014-05","conditions":"Hypertension","enrollment":28},{"nctId":"NCT02232880","phase":"PHASE2","title":"Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2014-08","conditions":"Hypertension","enrollment":1},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02916602","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-04","conditions":"Hypertension","enrollment":340},{"nctId":"NCT00000542","phase":"PHASE3","title":"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1993-08","conditions":"Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus","enrollment":""},{"nctId":"NCT01896661","phase":"PHASE3","title":"Effect of Antihypertensive Agents Over Sleep Apnea","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12","conditions":"Hypertension, Obstructive Sleep Apnea","enrollment":53},{"nctId":"NCT01750294","phase":"PHASE4","title":"A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD","status":"COMPLETED","sponsor":"Indiana University","startDate":"2012-08","conditions":"Chronic Kidney Disease, Poorly-Controlled Hypertension","enrollment":14},{"nctId":"NCT00000514","phase":"PHASE3","title":"Systolic Hypertension in the Elderly Program (SHEP)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1984-06","conditions":"Cardiovascular Diseases, Cerebrovascular Disorders, Heart Diseases","enrollment":""},{"nctId":"NCT00000522","phase":"PHASE2","title":"Treatment of Mild Hypertension Study (TOMHS)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"1985-08","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":""},{"nctId":"NCT01850160","phase":"PHASE3","title":"Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension","status":"COMPLETED","sponsor":"Farma de Colombia SA","startDate":"2013-04","conditions":"Hypertension","enrollment":124},{"nctId":"NCT02100462","phase":"PHASE4","title":"Chlorthalidone and HCTZ Impacts on Platelet Activation","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2014-03","conditions":"Hypertension","enrollment":30},{"nctId":"NCT02496910","phase":"PHASE1","title":"PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-06","conditions":"Hypertension","enrollment":180},{"nctId":"NCT02387554","phase":"PHASE1","title":"Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-08","conditions":"Hypertension(HTN)","enrollment":33},{"nctId":"NCT01822860","phase":"PHASE4","title":"Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function","status":"WITHDRAWN","sponsor":"Creighton University","startDate":"2013-03","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00971165","phase":"PHASE3","title":"Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-07","conditions":"Hypertension, Cardiovascular Disease","enrollment":655},{"nctId":"NCT00970931","phase":"PHASE3","title":"Hypertension Prevention in Pre-Hypertensive Individuals","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-07","conditions":"Pre-hypertension, Hypertension, Cardiovascular Disease","enrollment":730},{"nctId":"NCT01235377","phase":"PHASE4","title":"Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study","status":"COMPLETED","sponsor":"VA Pharmacy Benefits Management Strategic Healthcare Group","startDate":"2011-09","conditions":"Hypertension","enrollment":20},{"nctId":"NCT02152969","phase":"PHASE1","title":"Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2014-05","conditions":"Hypertension","enrollment":66},{"nctId":"NCT01456169","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Essential Hypertension","enrollment":507},{"nctId":"NCT00563901","phase":"","title":"Analyzing How Genetics May Affect Response to High Blood Pressure Medications","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2000-09","conditions":"Hypertension, Coronary Disease, Cerebrovascular Accident","enrollment":37939},{"nctId":"NCT01806363","phase":"PHASE1","title":"Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2012-11","conditions":"Hypertension","enrollment":60},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Safety","enrollment":153},{"nctId":"NCT00000499","phase":"PHASE2","title":"Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1980-09","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":""},{"nctId":"NCT00000513","phase":"PHASE3","title":"Trial of Antihypertensive Intervention Management","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1984-04","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":""},{"nctId":"NCT00000525","phase":"PHASE3","title":"Diuretics, Hypertension, and Arrhythmias Clinical Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"1986-07","conditions":"Cardiovascular Diseases, Death, Sudden, Cardiac, Heart Arrest","enrollment":233},{"nctId":"NCT00241839","phase":"PHASE3","title":"Uric Acid and Hypertension in African Americans","status":"COMPLETED","sponsor":"University of Florida","startDate":"2005-08","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":150},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Essential Hypertension","enrollment":609},{"nctId":"NCT00847626","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Hypertension","enrollment":1711}],"_emaApprovals":[],"_faersSignals":[{"count":991,"reaction":"FATIGUE"},{"count":934,"reaction":"DRUG INEFFECTIVE"},{"count":867,"reaction":"NAUSEA"},{"count":754,"reaction":"DIARRHOEA"},{"count":659,"reaction":"PAIN"},{"count":644,"reaction":"DIZZINESS"},{"count":621,"reaction":"HEADACHE"},{"count":606,"reaction":"DYSPNOEA"},{"count":599,"reaction":"OFF LABEL USE"},{"count":549,"reaction":"ARTHRALGIA"}],"genericFilers":[{"notes":"","market":"","status":"","company":"","filedDate":"","expectedLaunch":"","applicationNumber":""}],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"💊","route":"Oral","frequency":"once daily","formulation":"tablet"},"crossReferences":{"chemblId":"CHEMBL1055"},"formularyStatus":[],"_approvalHistory":[{"date":"20170330","type":"ORIG","sponsor":"NOVAST LABS","applicationNumber":"ANDA206904"},{"date":"20020822","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19910920","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19810226","type":"ORIG","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19840824","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19891219","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19980205","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19930621","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19920113","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19850315","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19991210","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19900131","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19880329","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19820624","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19980225","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19931220","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"19871019","type":"SUPPL","sponsor":"MYLAN","applicationNumber":"ANDA086831"},{"date":"20200211","type":"ORIG","sponsor":"ALKEM LABS LTD","applicationNumber":"ANDA213412"},{"date":"20190806","type":"ORIG","sponsor":"UNICHEM","applicationNumber":"ANDA211627"},{"date":"20211025","type":"ORIG","sponsor":"NOVITIUM PHARMA","applicationNumber":"ANDA215560"},{"date":"20240923","type":"SUPPL","sponsor":"NOVITIUM PHARMA","applicationNumber":"ANDA215560"}],"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"Unknown–present","companyName":"Unknown","relationship":"Originator"}],"publicationCount":1573,"therapeuticAreas":["Metabolic"],"trialPhaseCounts":{"":6,"NA":6,"PHASE1":5,"PHASE2":8,"PHASE3":11,"PHASE4":12,"EARLY_PHASE1":1,"PHASE2, PHASE3":1},"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"CHLORTHALIDONE","genericName":"CHLORTHALIDONE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1960","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-10-19T00:00:00.000Z","mah":"MYLAN","brand_name_local":null,"application_number":"ANDA086831"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-03-30T00:00:00.000Z","mah":"NOVAST LABS","brand_name_local":null,"application_number":"ANDA206904"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-11-25T00:00:00.000Z","mah":"UNICHEM","brand_name_local":null,"application_number":"ANDA213302"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-11-27T00:00:00.000Z","mah":"AJANTA PHARMA LTD","brand_name_local":null,"application_number":"ANDA214129"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-08-26T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA216262"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:23:20.316262+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}